Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare histologic subtype of nonsmall cell lung cancer with limited targeted treatment options. In this study, we aimed to investigate the prevalence of METex14 skipping mutation in PSC patients without common targetable mutations in EGFR, KRAS, ALK, ROS1, and RET.
INTRODUCTION
Pulmonary sarcomatoid carcinoma (PSC) is a rare but aggressive lung malignancy, accounting for 0.3%-3% of all nonsmall cell lung carcinomas, with an overall 5-year survival rate of approximately 20%. [1] [2] [3] [4] Conventional chemotherapy has produced unsatisfactory results. Further studies are needed to explore tumor mutational profiles and identify novel therapeutic targets. [5] MET is located on chromosome 7 and encodes a tyrosine kinase receptor for hepatocyte growth factor. [6] Alterations in MET, such as gene amplification, protein overexpression, and gain of function mutations, are found in many human cancers. [7, 8] METex14 skipping is a novel MET alteration that drives the oncogenic event in multiple cancers. [9, 10] MET exon 14 skipping is emerging as a clinically relevant biomarker to predict treatment response to MET inhibitors. [11, 12] However, such alterations show diverse sequence composition, ranging from single-nucleotide mutations to large insertion/deletions. [13] Hence, detecting MET exon 14 skipping mutations using DNA-based next-generation sequencing (NGS) methods is challenging for diagnostic testing, whereas RNA-based testing can circumvent the complexity of DNA-based changes. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. We aimed to evaluate the prevalence of METex14 skipping mutation in Chinese patients with PSC negative for common targetable mutated genes including EGFR, KRAS, ALK, ROS1, and RET. We screened a cohort of 46 PSC cases from formalin-fixed and paraffin-embedded (FFPE) tissues at our institution. MET mutation analysis using next-generation sequencing Hematoxylin and eosin (H and E)-stained slides of resected tumors were reviewed. FFPE blocks were cut, deparaffinized, and subjected to RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion; Thermo Fisher, Carlsbad, CA, USA). The Oncomine Focus Assay libraries were prepared using the Ion AmpliSeq targeted sequencing technology (Thermo Fisher Scientific). Briefly, 10 ng of RNA was reverse transcribed to complementary DNA (cDNA) using the SuperScript VILO cDNA Synthesis kit (Invitrogen; Thermo Fisher, Carlsbad, CA, USA), and targets were amplified using a multiplex primer pool. Barcode adapters were ligated and normalized to 100 pmol/L. Eight equimolar RNA libraries were pooled before template preparation and enrichment using the Ion OneTouch2 and enrichment system (Thermo Fisher Scientific). Sequencing of 200 base pairs was performed on the Ion PGM 318BC chip (Thermo Fisher).
MATERIALS AND METHODS

Subjects and ethical aspects
Next-generation sequencing analysis pipeline and quality control Sequencing data were first processed with the Ion Torrent Suite software version 5.2.0 (Thermo Fisher Scientific, Carlsbad, CA, USA) for reference mapping and base calling, during which time, validation-defined quality control (QC) specifications were used as acceptance criteria. Quality filters were used at the amplicon level to remove counts below the threshold for detection and at the base pair level for low-quality variant calls. Ion Reporter Software (Thermo Fisher Scientific) was used to detect the fusion with QC metrics.
Quantitative real-time polymerase chain reaction for the detection of METex14 skipping mutation RNA extracted from FFPE samples as described above was reverse transcribed into cDNA using the SuperScript VILO cDNA Synthesis kit (Invitrogen; Thermo Fisher, CA, USA). The products were screened for METex14 mutation using an ABI 
Statistical analysis
Statistical significance was determined by the unpaired Student's t-test to compare the age of diagnosis. Fisher's exact test was used to assess the association of METex14 skipping mutation status with clinical variables. Hazard ratios and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models, and significant differences for survival analysis were compared using log-rank test. P < 0.05 was considered statistically significant.
RESULTS
Clinical features of the cohort
The clinical and pathologic parameters of all 46 patients with PSC are summarized in Table 1 and detailed in Supplementary Table 1 . The median age at disease onset was 46 years (range, 45-80 years), 9 (20%) patients were women, and 26 (57%) were never smokers. A majority (74%) of patients reported no family history of cancer. Frequent lymph node invasion (50%) was evident, which is a typical feature of PSC biologic behavior. During this study, nine patients were lost to follow-up. In total, 22 patients died during the follow-up period. The overall median survival time for patients was 26.9 months (range, 7-77 months) [ Supplementary Figure 1] .
Prevalence of METex14 skipping mutation in Chinese pulmonary sarcomatoid carcinoma patients
The 46 PSC patients included in the study were free of targetable mutations such as alterations in EGFR, KRAS, ALK, ROS1, and RET (data not shown). Among the 52 cancer-relevant genes included in the targeted NGS panel, METex14 skipping mutation was the only mutation identified. An example of sequence alignments in a patient with METex14 skipping mutation is shown in Figure 1 . Of the 46 PSC patients free of mutations in EGFR, KRAS, ALK, ROS1, and RET, 4 (9%) patients exhibited the METex14 skipping mutation. The METex14 skipping mutation in these four patients was also confirmed by quantitative real-time polymerase chain reaction [ Figure 2 ]. H and E staining of cancer samples from these four patients showed sarcoma-like structure, characterized by pleomorphic or spindle cells [ Supplementary Figure 2] .
Clinicopathological implications of METex14 skipping mutation in pulmonary sarcomatoid carcinoma
The four PSC patients with METex14 skipping mutation are listed in Table 1 . We compared the clinicopathological characteristics of the cohort of patients with METex14 skipping mutation with those of patients without the METex14 skipping mutation. We found no significant relationships between METex14 skipping mutation and clinicopathological features including gender, age at diagnosis, smocking status, family history of cancer, recurrence rate, T stage, lymph node invasion Table 1 ]. The median disease-free survival (DFS) in METex14 skipping positive patients was 35 months (1050 days) compared with a median DFS of 13.7 months (412 days) in negative patients (HR = 0.74, 95% CI = 0.24-2.67; P = 0.680) [ Table 1 ].
DISCUSSION
Data on the prevalence and clinicopathological implications of METex14 skipping in PSC are limited because the disease is rare. Here, we present a single-institution cohort of Chinese patients with PSC negative for EGFR, KRAS, ALK, ROS1, and RET mutations. The prevalence of METex14 skipping mutation in our cohort (9%) was different from that described in previous studies, probably due to different inclusion and exclusion criteria for participation. [2, [14] [15] [16] [17] Given the original attempt to screen for PSC patients without other targeted treatment options, only PSC cases without common driver mutations including EGFR, KRAS, ALK, ROS1, and RET were included in this study. In addition, intratumoral heterogeneity (e.g., percentage of sarcomatoid component) might also have an impact on the estimation of mutation prevalence. The differences in the frequency of METex14 skipping mutation could also be due to the patient's ethnicity or the different sensitivity of the sequencing assay.
Molecular characterization of targetable genetic alterations in PSC has increased our understanding of patient groups likely to benefit from targeted treatments. Using three different genetic testing methods, we reported a frequency of 9% (4/46) for METex14 skipping mutation in PSC patients in whom common targeted treatments are not suitable due to lack of targets including EGFR, KRAS, ALK, ROS1, and RET. Importantly, this type of alteration is emerging as a clinically relevant biomarker to predict response to treatment with MET inhibitors, as illustrated by several clinical trials with the MET inhibitors crizotinib and cabozantinib in lung adenocarcinoma patients harboring the METex14 skipping mutation. [18, 19] Considering that METex14 skipping mutation has been reported to promote MET activation in multiple tumor types and confer sensitivity to MET inhibitors, [12, [20] [21] [22] our results provide a rationale for the potential use of MET inhibitors in PSC patients with METex14 skipping mutation. Indeed, a recent case report of rapid dramatic clinical improvement with crizotinib in a 74-year-old female with PSC harboring a METex14 skipping mutation further corroborates the clinical relevance of our findings. [2] 
CONCLUSIONS
This study demonstrated that METex14 skipping mutation was detected in 9% (4/46) of Chinese PSC patients without other common targetable mutations in EGFR, KRAS, ALK, ROS1, and RET. A larger population-based study is needed to explore the clinicopathological and prognostic implications of the METex14 skipping mutation in PSC. Our findings suggest the need for additional efforts to test the METex14 skipping mutation in PSC patients and to evaluate their responsiveness to MET inhibitors in large-scale clinical trials. 
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